scispace - formally typeset
Open AccessJournal ArticleDOI

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, +13 more
- 01 Jun 2013 - 
- Vol. 31, Iss: 16, pp 2024-2028
TLDR
Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
Abstract: 
Purpose CDK4 is amplified in 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS.

read more

Content maybe subject to copyright    Report

Citations
More filters
Book ChapterDOI

Sarcoma of Soft Tissue

Mrinal M. Gounder, +4 more
TL;DR: Refractory IRB# 20087 GSK208467: OpenLabel Multi-cohort Clinical Trial to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1Specific T Cells, alone or in combination with other agents, in HLAA2+ Participants with NY-eso-1 and/or LAGE-1a Positive Solid Tumors
Journal ArticleDOI

The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.

Kirsi Santti, +5 more
- 25 Mar 2019 - 
TL;DR: Desmoid tumors (DT) are nonmalignant mesenchymal neoplasms with a high recurrence rate and concentrate into the small bowel mesentery and the abdominal wall when associated with familial adenom...
Journal ArticleDOI

Integrating therapies for surgical adult soft tissue sarcoma patients.

Daniel P. Milgrom, +3 more
- 02 Nov 2018 - 
TL;DR: The role for surgical resection in cure and palliation as well as the relative benefits of adjuvant therapies such as chemotherapy and radiation therapy are discussed.
Journal ArticleDOI

Metastatic soft tissue sarcomas: update on new agents and clinical studies

Attila Kollár, +1 more
TL;DR: Olaratumab, a platelet-derived growth factor receptor (PDGFR) inhibitor, in combination with doxorubicin, has revolutionized the first-line treatment of advanced STS and will be presented in the following review.
Journal ArticleDOI

New Drug Approvals for Sarcoma in the Last 5 Years.

Prapassorn Thirasastr, +4 more
- 01 Jul 2022 - 
TL;DR: In this paper , the authors analyzed the published literature and abstracts reported in major congresses dedicated to sarcoma and connective tissue tumor management in the last 5 years and described the new drugs that made it through to the finish line and new agents with promising activity that are in later stages of investigation in the large family of malignant connective tissues tumors.
References
More filters
Journal ArticleDOI

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Elizabeth Eisenhauer, +15 more
- 01 Jan 2009 - 
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Book

Statistical methods for rates and proportions

Joseph L. Fleiss
TL;DR: In this paper, the basic theory of Maximum Likelihood Estimation (MLE) is used to detect a difference between two different proportions of a given proportion in a single proportion.
Journal ArticleDOI

Statistical Methods for Rates and Proportions.

B. S. Everitt, +1 more
- 01 Sep 1973 - 
Journal Article

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Hirokazu Watanabe, +9 more
- 01 Dec 2009 - 
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal Article

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Related Papers (5)

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, +11 more
- 29 Oct 2009 - 

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T. A. van der Graaf, +22 more
- 19 May 2012 - 

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, +17 more
- 01 Jan 2015 - 

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Stefan Sleijfer, +12 more
- 01 Jul 2009 -